- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 241780, 11 pages
Circulating microRNAs and Kallikreins before and after Radical Prostatectomy: Are They Really Prostate Cancer Markers?
1Department of Medical-Surgical Sciences and Public Health, Faculty of Medicine and Surgery, University of Perugia, Loc. S. Andrea delle Fratte, 06156 Perugia, Italy
2Department of Biopathological Science and Hygiene of Food and Animal Production, Faculty of Veterinary Medicine, University of Perugia, Via San Costanzo 4, 06126 Perugia, Italy
Received 10 May 2013; Revised 9 August 2013; Accepted 23 August 2013
Academic Editor: Romonia Renee Reams
Copyright © 2013 Maria Giulia Egidi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- E. P. Diamandis, G. M. Yousef, A. R. Soosaipillai, and P. Bunting, “Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma,” Clinical Biochemistry, vol. 33, no. 7, pp. 579–583, 2000.
- C. V. Obiezu, A. Scorilas, D. Katsaros et al., “Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients,” Clinical Cancer Research, vol. 7, no. 8, pp. 2380–2386, 2001.
- G. M. Yousef, A. Scorilas, K. Jung, L. K. Ashworth, and E. P. Diamandis, “Molecular cloning of the human kallikrein 15 gene (KLK15). Up-regulation in prostate cancer,” Journal of Biological Chemistry, vol. 276, no. 1, pp. 53–61, 2001.
- D. P. Bartel, “microRNAs: genomics, biogenesis, mechanism, and function,” Cell, vol. 116, no. 2, pp. 281–297, 2004.
- B. P. Lewis, C. B. Burge, and D. P. Bartel, “Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets,” Cell, vol. 120, no. 1, pp. 15–20, 2005.
- P. S. Mitchell, R. K. Parkin, E. M. Kroh et al., “Circulating microRNAs as stable blood-based markers for cancer detection,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 30, pp. 10513–10518, 2008.
- G. A. Calin, C. Sevignani, C. D. Dumitru et al., “Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 9, pp. 2999–3004, 2004.
- K. P. Porkka, M. J. Pfeiffer, K. K. Waltering, R. L. Vessella, T. L. J. Tammela, and T. Visakorpi, “MicroRNA expression profiling in prostate cancer,” Cancer Research, vol. 67, no. 13, pp. 6130–6135, 2007.
- “Profiling of microRNA in serum/plasma and other biofluids-Guidelines for the miRCURY LNATM Universal RT microRNA PCR System, 3rd edition,” http://www.exiqon.com/.
- E. Mearini, E. Cottini, G. Cochetti, C. Antognelli, and V. Talesa, “Biomarkers of prostate cancer. A review,” Minerva Urologica e Nefrologica, vol. 62, no. 2, pp. 163–178, 2010.
- E. P. Diamandis and G. M. Yousef, “Human tissue kallikreins: a family of new cancer biomarkers,” Clinical Chemistry, vol. 48, no. 8, pp. 1198–1205, 2002.
- G. Sotiropoulou, V. Rogakos, T. Tsetsenis et al., “Emerging interest in the Kallikrein gene family for understanding and diagnosing cancer,” Oncology Research, vol. 13, no. 6–10, pp. 381–391, 2002.
- I. P. Michael, G. Pampalakis, S. D. Mikolajczyk, J. Malm, G. Sotiropoulou, and E. P. Diamandis, “Human tissue kallikrein 5 is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progression,” Journal of Biological Chemistry, vol. 281, no. 18, pp. 12743–12750, 2006.
- C. Becker, T. Piironen, K. Pettersson et al., “Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum,” Journal of Urology, vol. 163, no. 1, pp. 311–316, 2000.
- A. J. Vickers, A. M. Cronin, G. Aus et al., “A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden,” BMC Medicine, vol. 6, p. 19, 2008.
- X. Bi, H. He, Y. Ye et al., “Association of TMPRSS2 and KLK11 gene expression levels with clinical progression of human prostate cancer,” Medical Oncology, vol. 27, no. 1, pp. 145–151, 2010.
- A. Chang, G. M. Yousef, A. Scorilas et al., “Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: an independent indicator of favourable prognosis in breast cancer,” British Journal of Cancer, vol. 86, no. 9, pp. 1457–1464, 2002.
- K. M. Nelson and G. J. Weiss, “microRNAs and cancer: past, present, and potential future,” Molecular Cancer Therapeutics, vol. 7, no. 12, pp. 3655–3660, 2008.
- J. W. F. Catto, A. Alcaraz, A. S. Bjartell et al., “MicroRNA in prostate, bladder, and kidney cancer: a systematic review,” European Urology, vol. 59, no. 5, pp. 671–681, 2011.
- C. H. Lawrie, S. Gal, H. M. Dunlop et al., “Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma,” British Journal of Haematology, vol. 141, no. 5, pp. 672–675, 2008.
- N. Kosaka, H. Iguchi, and T. Ochiya, “Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis,” Cancer Science, vol. 101, no. 10, pp. 2087–2092, 2010.
- A. E. Szafranska, T. S. Davison, J. John et al., “MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma,” Oncogene, vol. 26, no. 30, pp. 4442–4452, 2007.
- D. Lebanony, H. Benjamin, S. Gilad et al., “Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma,” Journal of Clinical Oncology, vol. 27, no. 12, pp. 2030–2037, 2009.
- H. Benjamin, D. Lebanony, L. Cohen, et al., “Differential diagnosis of mesothelioma using a microRNA assay,” in Proceedings of the 44th American Society of Clinical Oncology Annual Meeting, Chicago, Ill, USA, June 2008, Abstract 22000.
- N. Rosenfeld, R. Aharonov, E. Meiri et al., “microRNAs accurately identify cancer tissue origin,” Nature Biotechnology, vol. 26, no. 4, pp. 462–469, 2008.
- F. J. Sheedy and L. A. J. O'Neill, “Adding fuel to fire: microRNAs as a new class of mediators of inflammation,” Annals of the Rheumatic Diseases, vol. 67, supplement 3, pp. iii50–iii55, 2008.
- S. Zhu, M. Si, H. Wu, and Y. Mo, “MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1),” Journal of Biological Chemistry, vol. 282, no. 19, pp. 14328–14336, 2007.
- F. Meng, R. Henson, H. Wehbe-Janek, K. Ghoshal, S. T. Jacob, and T. Patel, “MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer,” Gastroenterology, vol. 133, no. 2, pp. 647–658, 2007.
- Z. Zhang, Z. Li, C. Gao et al., “miR-21 plays a pivotal role in gastric cancer pathogenesis and progression,” Laboratory Investigation, vol. 88, no. 12, pp. 1358–1366, 2008.
- B. Wang and Q. Zhang, “The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors,” Journal of Cancer Research and Clinical Oncology, vol. 138, no. 10, pp. 1659–1666, 2012.
- F. Wu, M. Zikusoka, A. Trindade et al., “microRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha,” Gastroenterology, vol. 135, no. 5, pp. 1435–1438, 2008.
- M. P. Gantier, A. J. Sadler, and B. R. G. Williams, “Fine-tuning of the innate immune response by microRNAs,” Immunology and Cell Biology, vol. 85, no. 6, pp. 458–462, 2007.
- R. M. O'Connell, D. S. Rao, A. A. Chaudhuri, and D. Baltimore, “Physiological and pathological roles for microRNAs in the immune system,” Nature Reviews Immunology, vol. 10, no. 2, pp. 111–122, 2010.
- X. Chen, Y. Ba, L. Ma et al., “Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases,” Cell Research, vol. 18, no. 10, pp. 997–1006, 2008.
- J. Lu, G. Getz, E. A. Miska et al., “MicroRNA expression profiles classify human cancers,” Nature, vol. 435, no. 7043, pp. 834–838, 2005.
- B. Mateescu, L. Batista, M. Cardon et al., “MiR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response,” Nature Medicine, vol. 17, no. 12, pp. 1627–1635, 2011.
- J. C. Brase, M. Johannes, T. Schlomm et al., “Circulating miRNAs are correlated with tumor progression in prostate cancer,” International Journal of Cancer, vol. 128, no. 3, pp. 608–616, 2011.
- L. A. Selth, S. Townley, J. L. Gillis et al., “Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease,” International Journal of Cancer, vol. 131, no. 3, pp. 652–661, 2012.
- R. J. Bryant, T. Pawlowski, J. W. F. Catto et al., “Changes in circulating microRNA levels associated with prostate cancer,” British Journal of Cancer, vol. 106, no. 4, pp. 768–774, 2012.
- H. C. Nguyen, W. Xie, M. Yang et al., “Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer,” The Prostate, vol. 73, no. 4, pp. 346–354, 2013.
- F. Y. Agaoglu, M. Kovancilar, Y. Dizdar et al., “Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer,” Tumor Biology, vol. 32, no. 3, pp. 583–588, 2011.
- R. Mahn, L. C. Heukamp, S. Rogenhofer, A. Von Ruecker, S. C. Müller, and J. Ellinger, “Circulating microRNAs (miRNA) in serum of patients with prostate cancer,” Urology, vol. 77, no. 5, pp. 1265–e16, 2011.
- F. Meng, R. Henson, M. Lang et al., “Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines,” Gastroenterology, vol. 130, no. 7, pp. 2113–2129, 2006.
- P. E. Blower, J. Chung, J. S. Verducci et al., “microRNAs modulate the chemosensitivity of tumor cells,” Molecular Cancer Therapeutics, vol. 7, no. 1, pp. 1–9, 2008.
- A. Watahiki, R. J. Macfarlane, M. E. Gleave et al., “Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer,” International Journal of Molecular Sciences, vol. 14, no. 4, pp. 7757–7770, 2013.
- M. Folini, P. Gandellini, N. Longoni et al., “miR-21: an oncomir on strike in prostate cancer,” Molecular Cancer, vol. 9, p. 12, 2010.
- H. Konishi, D. Ichikawa, S. Komatsu et al., “Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre- and post-operative plasma,” British Journal of Cancer, vol. 106, no. 4, pp. 740–747, 2012.